The FDA has cleared INmune Bio's IND application for INKmune, a natural killer cell immunotherapy, for a clinical trial in the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC). The company will host a webinar to discuss the treatment and trial details.